[Organization of the Federal Drug and Medical Products Institute in view of increased European competition].
作者信息
Kurth R
机构信息
Robert Koch-Institut, Berlin, Germany.
出版信息
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Mar;51(3):340-4. doi: 10.1007/s00103-008-0472-2.
PMID:18369569
Abstract
摘要
相似文献
1
[Organization of the Federal Drug and Medical Products Institute in view of increased European competition].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Mar;51(3):340-4. doi: 10.1007/s00103-008-0472-2.
2
The impact of FDA reform.
Med Device Technol. 2003 Apr;14(3):36-7.
3
Drug review "behind the curtain": a response to Professor Struve.
Cornell Law Rev. 2008 Jul;93(5):1075-90.
4
Regulators need to regulate. For health and safety issues, the nation needs watchdogs to be on guard.
Mod Healthc. 2010 Mar 1;40(9):16.
5
Using a drug-safety tool to prevent competition.
N Engl J Med. 2014 Apr 17;370(16):1476-8. doi: 10.1056/NEJMp1400488.
6
Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Seton Hall Law Rev. 2011;41(2):559-92.
7
The federal preemption debate in pharmaceutical labeling product liability actions.
Tort Trial Insur Pract Law J. 2007 Fall;43(1):35-70.
8
[The use of nanotechnology in medicinal products in the light of European Union law].
Pol Merkur Lekarski. 2014 Dec;37(222):369-72.
9
[European drug policy: welcomed modernization but shortage of political proposals concerning industry and research].
Lakartidningen. 2003 Oct 30;100(44):3541-2.
10
Industry reneges on postmarketing trial commitments.
Nat Biotechnol. 2003 Jul;21(7):718. doi: 10.1038/nbt0703-718.
Zotero 插件